CureVac Shares Cease Trading Following BioNTech Acquisition Finalization

CureVac NL0015436031

CureVac's tenure as an independent, publicly traded mRNA company has concluded. The firm's shares were officially delisted from the Nasdaq exchange yesterday, marking the final step in its complete acquisition by competitor BioNTech. The business will now be fully absorbed into BioNTech's operations.

The formal takeover process unfolded rapidly over recent weeks. Key milestones proceeded as follows:

• December 18, 2025: BioNTech closed its exchange offer, receiving 86.75% of CureVac's outstanding shares.
• January 6, 2026: CureVac notified the Nasdaq of the post-restructuring completion and requested an immediate trading suspension. Concurrently, the company filed a Form 25 with the U.S. Securities and Exchange Commission (SEC) to initiate delisting.
• January 16, 2026: The delisting from Nasdaq became legally effective.

In total, 195,341,219 CureVac shares were tendered. The full equity transaction valued CureVac at approximately $1.25 billion. Shareholders received 0.05363 BioNTech American Depositary Shares (ADS) for each CureVac share held, equating to a value of $5.46 per share at the time of the offer's announcement.

Finalizing Ownership and Regulatory Status

BioNTech acquired the remaining 13.25% of shares through a statutory squeeze-out procedure via a merger. The legal successor to the former CureVac N.V. is now CureVac Merger B.V., meaning publicly traded CureVac stock no longer exists.

The company also intends to file a Form 15 with the SEC to terminate all remaining reporting obligations. This deregistration is expected to take effect 90 days after submission.

Leadership Transition and Integration Plans

Following the acquisition's completion, CureVac's previous management team voluntarily stepped down. The new board of CureVac SE comprises:

• Prof. Ugur Sahin, M.D.
• Sierk Poetting, Ph.D.
• Ramón Zapata-Gomez

BioNTech has stated its intention to maintain CureVac's existing structures during an initial integration phase. This period will be used for strategic and scientific reviews to determine the future direction of the combined mRNA portfolio.

Strategic Rationale for BioNTech

The acquisition delivers several defined advantages for BioNTech:

• Intellectual Property: Resolution of ongoing intellectual property disputes between the two firms.
• Manufacturing Capacity: Incorporation of CureVac's Tübingen, Germany sites into BioNTech's production network.
• Oncology Pipeline: Access to additional mRNA-based candidates for cancer therapies.
• Technology Platform: Complementary expertise in mRNA design and formulation technologies.

Full integration of the Tübingen location into BioNTech's global research and development network is targeted for the first quarter of 2026. Detailed updates on the integration progress are anticipated alongside BioNTech's fourth-quarter 2025 financial results, scheduled for release by the end of February 2026.